Paraspinal radiation recall myositis after gemcitabine for pancreatic adenocarcinoma

被引:2
作者
Barrios-Anderson, Adriel [1 ]
Radhakrishnan, Reshmitha [1 ]
Yu, Esther [1 ]
Shimanovsky, Alexei [1 ]
机构
[1] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA
关键词
chemotherapy; pancreatic cancer; radiotherapy; THERAPY; PATIENT;
D O I
10.1136/bcr-2020-240896
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Radiation recall (RR) is a chemotherapy-induced reaction that leads to inflammation and necrosis in previously irradiated tissue. Gemcitabine is a cytidine analogue that is often used in conjunction with nab-paclitaxel in the treatment of pancreatic cancer. Herein, we present a case of a 56-year-old woman with stage III pancreatic adenocarcinoma diagnosed with gemcitabine-induced RR when she presented with lower back pain and new rim-enhancing collections within the right and left paraspinal musculature 5 months after radiation therapy to the pancreas. A PubMed search was performed for 'Radiation Recall Myositis' and a complete literature review performed. This case and review of the literature of published cases of RR myositis highlight the clinical course and presentation of RR myositis. This review highlights the importance of considering RR in the differential diagnosis when patients who are undergoing chemotherapy and radiation present with inflammatory changes in previously irradiated areas.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] Thermosensitive Liposomes for Gemcitabine Delivery to Pancreatic Ductal Adenocarcinoma
    Aparicio-Lopez, Cesar B.
    Timmerman, Sarah
    Lorino, Gabriella
    Rogers, Tatiana
    Pyle, Marla
    Shrestha, Tej B.
    Basel, Matthew T.
    CANCERS, 2024, 16 (17)
  • [22] Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma
    de Jong, Evelien J. M.
    Janssen, Quisette P.
    Simons, Tessa F. A.
    Besselink, Marc G.
    Bonsing, Bert A.
    Bouwense, Stefan A. W.
    Geurts, Sandra M. E.
    Homs, Marjolein Y., V
    de Meijer, Vincent E.
    Tjan-Heijnen, Vivianne C. G.
    van Laarhoven, Hanneke W. M.
    Valkenburg-van Iersel, Liselot B. J.
    Wilmink, Johanna W.
    van der Geest, Lydia G.
    Koerkamp, Bas Groot
    de Vos-Geelen, Judith
    INTERNATIONAL JOURNAL OF CANCER, 2022, 150 (10) : 1654 - 1663
  • [23] Concurrent Radiotherapy and Gemcitabine for Unresectable Pancreatic Adenocarcinoma: Impact of Adjuvant Chemotherapy on Survival
    Ogawa, Kazuhiko
    Ito, Yoshinori
    Hirokawa, Naoki
    Shibuya, Keiko
    Kokubo, Masaki
    Ogo, Etsuyo
    Shibuya, Hitoshi
    Saito, Tsutomu
    Onishi, Hiroshi
    Karasawa, Katsuyuki
    Nemoto, Kenji
    Nishimura, Yasumasa
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 83 (02): : 559 - 565
  • [24] Adjuvant radiotherapy and chemoradiation with gemcitabine after R1 resection in patients with pancreatic adenocarcinoma
    Daniel Habermehl
    Ingo C Brecht
    Frank Bergmann
    Stefan Rieken
    Jens Werner
    Markus W Büchler
    Christoph Springfeld
    Dirk Jäger
    Jürgen Debus
    Stephanie E Combs
    World Journal of Surgical Oncology, 13
  • [25] A Phase 2 Trial of Gemcitabine, 5-Fluorouracil, and Radiation Therapy in Locally Advanced Nonmetastatic Pancreatic Adenocarcinoma
    Mamon, Harvey J.
    Niedzwiecki, Donna
    Hollis, Donna
    Tan, Benjamin R.
    Mayer, Robert J.
    Tepper, Joel E.
    Goldberg, Richard M.
    Blackstock, A. William
    Fuchs, Charles S.
    CANCER, 2011, 117 (12) : 2620 - 2628
  • [26] Radiation recall reaction induced by gemcitabine/docetaxel in children: A retrospective study on risk factors and outcomes
    Larrosa, Cristina
    Mico, Soraya
    Ramos, Monica
    Perez-Jaume, Sara
    Sanchez, Monica
    Castaneda, Alicia
    Garraus, Moira
    Mora, Jaume
    PEDIATRIC BLOOD & CANCER, 2024, 71 (10)
  • [27] A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma
    Mahalingam, Devalingam
    Goel, Sanjay
    Aparo, Santiago
    Arora, Sukeshi Patel
    Noronha, Nicole
    Hue Tran
    Chakrabarty, Romit
    Selvaggi, Giovanni
    Gutierrez, Andres
    Coffey, Matthew
    Nawrocki, Steffan T.
    Nuovo, Gerard
    Mita, Monica M.
    CANCERS, 2018, 10 (06)
  • [28] A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma
    Nicolle, R.
    Gayet, O.
    Duconseil, P.
    Vanbrugghe, C.
    Roques, J.
    Bigonnet, M.
    Blum, Y.
    Elarouci, N.
    Armenoult, L.
    Ayadi, M.
    de Reynies, A.
    Puleo, F.
    Augustin, J.
    Emile, J. F.
    Svrcek, M.
    Arsenijevic, T.
    Hammel, P.
    Giovannini, M.
    Grandval, P.
    Dahan, L.
    Moutardier, V
    Gilabert, M.
    Van Laethem, J. L.
    Bachet, J. B.
    Cros, J.
    Iovanna, J.
    Dusetti, N. J.
    ANNALS OF ONCOLOGY, 2021, 32 (02) : 250 - 260
  • [29] Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma
    Liu, Kaidong
    Geng, Yiding
    Wang, Linzhu
    Xu, Huanhuan
    Zou, Min
    Li, Yawei
    Zhao, Zhangxiang
    Chen, Tingting
    Xu, Fengyan
    Sun, Liang
    Wu, Shuliang
    Gu, Yunyan
    MOLECULAR ONCOLOGY, 2022, 16 (16) : 3034 - 3051
  • [30] Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma
    Gilabert, Marine
    Chanez, Brice
    Rho, Young Soo
    Giovanini, Marc
    Turrini, Olivier
    Batist, Gerald
    Kavan, Petr
    Raoul, Jean Luc
    MEDICINE, 2017, 96 (16)